To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05243342
Title A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries NOR | ESP | DNK | AUS

Facility Status City State Zip Country Details
Royal Adelaide Hospital Adelaide South Australia 5000 Australia Details
Alfred Hospital Melbourne Victoria 3004 Australia Details
Odense Universitetshospital Odense C South Denmark 5000 Denmark Details
Sygehus Lillebælt, Vejle Vejle South Denmark 7100 Denmark Details
Oslo Universitetssykehus HF Oslo 0450 Norway Details
Hospital Universitario Germans Trias i Pujol Badalona Barcelona 08916 Spain Details
Hospital Universitari Vall d'Hebron Barcelona 08035 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field